Ocuphire to Participate in Upcoming Virtual HCW Conference in November

Rhea-AI Summary

Ocuphire Pharma will participate in the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 3:30 PM. This follows their recent merger with Rexahn Pharmaceuticals and a private placement closure. Ocuphire, trading under the ticker symbol OCUP on Nasdaq, focuses on developing therapies for eye disorders. Their lead product, Nyxol® Eye Drops, targets conditions such as night vision disturbances, while the second candidate, APX3330, is aimed at retinal diseases.

FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwright 6^th Annual Israel Conference on November 12^th, 2020.

H.C. Wainwright 6th Annual Israel Conference – Thursday November 12, 2020
Presentation Time: 3:30pm
Weblink: https://journey.ct.events/view/9f6a3928-837c-4a93-9b61-8129988e8f9d

The Company recently announced the closing of a previously announced private placement, and the completion of its merger with Rexahn Pharmaceuticals, Inc. (NasdaqCM; REXN), and is trading on Nasdaq Capital Market under the ticker symbol “OCUP”. Ocuphire also recently hosted a KOL call with Key Opinion Leaders Dr. Jay Pepose, M.D., Ph.D, Paul M. Karpecki, O.D., F.A.A.O., and Peter Kaiser, M.D. covering the refractive and retinal landscape.  Webcast replay is available at www.ocuphire.com.

About Ocuphire Pharma
Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase 2 clinical trials. For more information, please visit www.ocuphire.com.

Ocuphire Contact:
Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
(248) 681-9815
msooch@ocuphire.com
www.ocuphire.com

FAQ

What is the date of Ocuphire's participation in the H.C. Wainwright Israel Conference?

Ocuphire will participate in the H.C. Wainwright Israel Conference on November 12, 2020.

What time will Ocuphire present at the conference?

Ocuphire's presentation at the conference is scheduled for 3:30 PM.

What is the focus of Ocuphire Pharma's product candidates?

Ocuphire Pharma focuses on developing therapies for various eye disorders.

What are Ocuphire's lead drug candidates?

Ocuphire's lead candidates are Nyxol® Eye Drops and APX3330.

Under what ticker symbol is Ocuphire traded?

Ocuphire is traded on the Nasdaq under the ticker symbol OCUP.